Why is Orchid Pharma falling/rising?

As of 20-Aug, Orchid Pharma Ltd's stock price is currently at 758.10, reflecting a decrease of 0.75, or 0.1%. The stock has recently outperformed its sector by 0.32%, but it has experienced a trend reversal after two consecutive days of gains. The stock's performance over the past week shows a decline of 1.12%, while it has increased by 3.37% over the past month. However, its year-to-date performance is significantly negative at -58.28%. The company has high institutional holdings at 20.82%, indicating a level of confidence from larger investors, but it also faces weak long-term fundamentals, including a low return on equity (ROE) of 4.68% and a concerning EBIT to interest ratio of 1.99. The recent financial results have been negative, with a 19.64% drop in operating profit and a 40.2% decline in profit after tax compared to previous quarters.
Broader market context shows that while the Sensex has gained 1.64% over the past week, Orchid Pharma's stock has underperformed significantly, with a year-over-year return of -45.81% compared to the market's modest gain of 1.31%. The stock's liquidity appears adequate for trading, but a notable drop in delivery volume by 61.03% against the five-day average suggests a decrease in investor participation. This lack of engagement, combined with the company's ongoing negative financial performance and weak growth prospects, contributes to the stock's downward movement in the current market environment.